Evidence map›Paper›PMID 27294383›Full record

ReviewDer Internist2016

[Drug-drug interactions in the elderly : Which ones really matter?].

K Bitter, J F Schlender, R Woltersdorf

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Internist, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Assessing Electronic Prescription: A Cross-sectional Study of Pharmacists in Germany].Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) · 2022
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

K BitterKlinische Pharmazie, Pharmazeutisches Institut, Universität Bonn, An der Immenburg 4, 53121, Bonn, Deutschland.
J F SchlenderKlinische Pharmazie, Pharmazeutisches Institut, Universität Bonn, An der Immenburg 4, 53121, Bonn, Deutschland.
R WoltersdorfKlinische Pharmazie, Pharmazeutisches Institut, Universität Bonn, An der Immenburg 4, 53121, Bonn, Deutschland. r.woltersdorf@uni-bonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacotherapy in the elderly is challenging due to age-related physiological changes, high interindividual variability, and increasing frequency of multimorbidity. The resulting polypharmacy increases the risk of drug-drug interactions and requires an individual risk assessment. Some drug-drug interactions are documented to be associated with harm in older adults including intoxication, gastrointestinal bleeding, or falls. Therefore, they are considered to be of special importance in the elderly. Moreover, frequent risk factors and continuous physiological alterations in the elderly should be taken into account during risk assessment. This review exemplifies clinically relevant drug-drug interactions and risk factors in the elderly. In addition, assessment tools as well as prevention and management strategies for clinical practice are presented.

Indexed as

Drug InteractionsPatient SafetyPolypharmacyAgedAged, 80 and overClinical Decision-MakingClinical ProtocolsDecision Support Systems, ClinicalDrug-Related Side Effects and Adverse ReactionsFemaleGeriatric AssessmentHumansMaleMiddle AgedRisk AssessmentDrug-related problemsDrug-related side effects and adverse reactionsPatient safetyPharmacotherapyPolypharmacy

Identifiers

PMID27294383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.